Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia
Abstract:Background
Determining the extent of seropositivity of SARS-CoV-2 antibody has the potential to guide prevention and control efforts. We aimed to determine the seroprevalence of SARS-CoV-2 antibody among individuals aged above15 years and residing in the congregate settings of Dire Dawa city administration, Ethiopia.
Method
We analyzed COVID-19 seroprevalence data on 684 individuals from a community based cross-sectional survey conducted among indi… Show more
“…In our finding, a positive but non-statistically significant association was found between age during a quarantined of SARS-CoV-2 antibody sero-positivity test ( p = 0.06). The level of risk identified in our study was similar to other studies congregated population at Dire Dawa Ethiopia, 5 Israel, 28 and Southern India. 32 Although such lack of effect of age could be related to our particular choice of age category, the differences mean that the risk of getting infection might not vary by age.…”
Section: Discussionsupporting
confidence: 90%
“…5,16 After an influx or entry of COVID-19 disease in Ethiopia, quarantining has been imposed citywide and in areas where potential exposure to the contagious disease has likely happened in a large population, to ascertain if they become unwell. 1 This will help to reduce the risk of them infecting others by the implementation of separation and restriction of movement, 7,17 besides curb on the social gathering of the population, 5 and enforcement of quarantining for individuals having contact and travel history during the first wave of COVID-19 pandemic. 1 Different studies have also assessed the seroprevalence among close contacts and quarantined population, 18 as part of the national sample, and findings have documented a higher infection rate reported than the general population.…”
Section: Introductionmentioning
confidence: 99%
“…1 Different studies have also assessed the seroprevalence among close contacts and quarantined population, 18 as part of the national sample, and findings have documented a higher infection rate reported than the general population. 5,19 Moreover, evidence on the risk factors for acquiring COVID-19 disease among isolated populations specifically at high-risk individuals remains elusive and poorly defined. 18 As a response to this pandemic, Ethiopia enforced strict quarantine, contact tracing, and physical distancing policies resulting in one of the lowest numbers of individuals infected with SARS-CoV-2 globally.…”
Objective: The spread of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) in Ethiopia is below par understood and to date has been poorly characterized by a lower number of confirmed cases and deaths as compared with other regions of the Sub-Saharan African (SSA) countries. We aimed to investigate the seroprevalence of SARS-CoV-2 specific IgG antibodies, using the Abbott anti-nucleocapsid IgG chemiluminescent microparticle immunoassay, in two COVID-19 diagnosed and treatment centers of quarantined population during the first wave of the COVID-19 pandemic (since 30 April–30 May 2020). Methods: We analyzed data of 446 quarantined individuals during the first wave of COVID-19 pandemic. The data were collected using both interviewed and blood sample collection. Participants asked about demographic characteristics, COVID-19 infection symptoms, and its practice of preventive measures. Seroprevalence was determined using the severe acute respiratory syndrome coronavirus 2 IgG test. Results: The mean (± standard deviation) age of the respondent was 37.5 (±18.5) years. The estimated SARS-CoV-2 infection seroprevalence was found 4.7% (95% confidence interval: 3.1–6.2) with no significant difference on age and gender of participants. Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence was significantly associated with individuals who have been worked by moving from home to work area (adjusted odds ratio = 7.8, 95% confidence interval: 4.2–14.3, p < 0.019), not wearing masks (adjusted odds ratio = 2.4, 95% confidence interval: 1.9–3.8, p < 0.02), and baseline comorbidity (adjusted odds ratio = 6.3, 95% confidence interval: 2.3–17.1, p < 0.01) as compared to their counter groups, respectively. Conclusion: Our study concluded that lower coronavirus disease 2019 seroprevalence, yet the large population in the community to be infected and insignificant proportion of seroprevalence, was observed between age and sex of respondents. Protective measures like contact tracing, face covering, and social distancing are therefore vital to demote the risk of community—strengthening factors should be continued as effect modification of anticipation for severe course of coronavirus disease 2019.
“…In our finding, a positive but non-statistically significant association was found between age during a quarantined of SARS-CoV-2 antibody sero-positivity test ( p = 0.06). The level of risk identified in our study was similar to other studies congregated population at Dire Dawa Ethiopia, 5 Israel, 28 and Southern India. 32 Although such lack of effect of age could be related to our particular choice of age category, the differences mean that the risk of getting infection might not vary by age.…”
Section: Discussionsupporting
confidence: 90%
“…5,16 After an influx or entry of COVID-19 disease in Ethiopia, quarantining has been imposed citywide and in areas where potential exposure to the contagious disease has likely happened in a large population, to ascertain if they become unwell. 1 This will help to reduce the risk of them infecting others by the implementation of separation and restriction of movement, 7,17 besides curb on the social gathering of the population, 5 and enforcement of quarantining for individuals having contact and travel history during the first wave of COVID-19 pandemic. 1 Different studies have also assessed the seroprevalence among close contacts and quarantined population, 18 as part of the national sample, and findings have documented a higher infection rate reported than the general population.…”
Section: Introductionmentioning
confidence: 99%
“…1 Different studies have also assessed the seroprevalence among close contacts and quarantined population, 18 as part of the national sample, and findings have documented a higher infection rate reported than the general population. 5,19 Moreover, evidence on the risk factors for acquiring COVID-19 disease among isolated populations specifically at high-risk individuals remains elusive and poorly defined. 18 As a response to this pandemic, Ethiopia enforced strict quarantine, contact tracing, and physical distancing policies resulting in one of the lowest numbers of individuals infected with SARS-CoV-2 globally.…”
Objective: The spread of Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) in Ethiopia is below par understood and to date has been poorly characterized by a lower number of confirmed cases and deaths as compared with other regions of the Sub-Saharan African (SSA) countries. We aimed to investigate the seroprevalence of SARS-CoV-2 specific IgG antibodies, using the Abbott anti-nucleocapsid IgG chemiluminescent microparticle immunoassay, in two COVID-19 diagnosed and treatment centers of quarantined population during the first wave of the COVID-19 pandemic (since 30 April–30 May 2020). Methods: We analyzed data of 446 quarantined individuals during the first wave of COVID-19 pandemic. The data were collected using both interviewed and blood sample collection. Participants asked about demographic characteristics, COVID-19 infection symptoms, and its practice of preventive measures. Seroprevalence was determined using the severe acute respiratory syndrome coronavirus 2 IgG test. Results: The mean (± standard deviation) age of the respondent was 37.5 (±18.5) years. The estimated SARS-CoV-2 infection seroprevalence was found 4.7% (95% confidence interval: 3.1–6.2) with no significant difference on age and gender of participants. Severe acute respiratory syndrome coronavirus 2 antibody seroprevalence was significantly associated with individuals who have been worked by moving from home to work area (adjusted odds ratio = 7.8, 95% confidence interval: 4.2–14.3, p < 0.019), not wearing masks (adjusted odds ratio = 2.4, 95% confidence interval: 1.9–3.8, p < 0.02), and baseline comorbidity (adjusted odds ratio = 6.3, 95% confidence interval: 2.3–17.1, p < 0.01) as compared to their counter groups, respectively. Conclusion: Our study concluded that lower coronavirus disease 2019 seroprevalence, yet the large population in the community to be infected and insignificant proportion of seroprevalence, was observed between age and sex of respondents. Protective measures like contact tracing, face covering, and social distancing are therefore vital to demote the risk of community—strengthening factors should be continued as effect modification of anticipation for severe course of coronavirus disease 2019.
“…During the same year, higher seropositivity rates were observed in New York City (May–July 2020; 18+ years; 23.6% [ 10 ] and June–October 2020; 18+ years; 24.3% [ 11 ]), Saudi-Arabia (May–July 2020; 18+ years; 19.3%) [ 12 ], Ireland (June–July 2020; 18+ years; 12.6%) [ 13 ], and Mexico (August–November 2020; 20–39 (27.9%), 40–59 (27.8%) and 60+ (18.6%) years) [ 14 ]. Similar rates were observed in Ethiopia (June–July 2020; 15+ years, 3.2%) [ 15 ], England (April–September 2020; 18–65 years; 5.9%) [ 16 ], Amsterdam, the Netherlands (June and October 2020; 18–70 years, 9.4%) [ 17 ], Germany (May–June 2020; 18+ years; 11.3%) [ 10 ], and the United States (July 2020 (3.5%), December 2020 (11.5%); 16+ years) [ 18 ]. In Australia, between April and June 2020, the seropositivity rate among 20 year olds and above was lower than 1% [ 19 ].…”
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech vaccine, and on 20 December, an immunization campaign began among adults in Israel. We characterized seropositivity for IgG anti-spike antibodies against SARS-CoV-2 between January 2020 and July 2021, before and after the introduction of the vaccine in Israel among adults. We tested 9520 serum samples, collected between January 2020 and July 2021. Between January and August 2020, seropositivity rates were lower than 5.0%; this rate increased from September 2020 (6.3%) to April 2021 (84.9%) and reached 79.1% in July 2021. Between January and December 2020, low socio-economic rank was an independent, significant correlate for seropositivity. Between January and July 2021, the 40.00–64.99-year-old age group, Jews and others, and residents of the Northern district were significantly more likely to be seropositive. Our findings indicate a slow, non-significant increase in the seropositivity rate to SARS-CoV-2 between January and December 2020. Following the introduction of the Pfizer-BioNTech vaccine in Israel, a significant increase in seropositivity was observed from January until April 2021, with stable rates thereafter, up to July 2021.
A reliable estimate of SARS-CoV-2-specific antibodies is increasingly important to track the spread of infection and define the true burden of the ongoing COVID-19 pandemic. A systematic review and a meta-analysis were conducted with the objective of estimating the seroprevalence of SARS-CoV-2 infection in Africa. A systematic search of the PubMed, Scopus, Web of Science and Google Scholar electronic databases was conducted. Thirty-five eligible studies were included. Using meta-analysis of proportions, the overall seroprevalence of anti-SARS-CoV-2 antibodies was calculated as 16% (95% CI 13.1–18.9%). Based on antibody isotypes, 14.6% (95% CI 12.2–17.1%) and 11.5% (95% CI 8.7–14.2%) were seropositive for SARS-CoV-2 IgG and IgM, respectively, while 6.6% (95% CI 4.9–8.3%) were tested positive for both IgM and IgG. Healthcare workers (16.3%) had higher seroprevalence than the general population (11.7%), blood donors (7.5%) and pregnant women (5.7%). The finding of this systematic review and meta-analysis (SRMA) may not accurately reflect the true seroprevalence status of SARS-CoV-2 infection in Africa, hence, further seroprevalence studies across Africa are required to assess and monitor the growing COVID-19 burden.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.